# Solutions URL: https://nurevo.health/solutions Last updated: 2026-11-01 > Nurevo is the brand of Nurevo Technology Limited, company number SC892389. Nurevo is being designed for organisations that need a low-burden way to prioritise who should be seen sooner. ## Who it is for ### Health systems and memory services Nurevo is being designed so health systems and memory services can prioritise referrals. ### Primary care Nurevo is being designed for primary care, as a low-burden conversation that can offer an early signal before a specialist referral. ### Care homes and community organisations Nurevo is being designed for care homes and community organisations, where a short conversation on a phone or laptop can be offered in the place where the person already is. ### Pharmaceutical companies and research partners Nurevo is being designed for pharmaceutical companies and contract research organisations, to support recruitment and stratification for early-stage trials. Nurevo is in development and not yet available for clinical use. We welcome conversations about future pilots and research. ## Research and responsible AI How Nurevo is being developed: what the system is for, what goes in and out, its limits, and the steps still to come. Nurevo is at pre-seed stage. There is a working prototype of the data pipeline. Nurevo is preparing clinical validation. Version: Prototype. Last reviewed 1 November 2026. ### System card #### Intended use Nurevo is a screening and triage tool. A short conversation produces an explainable risk score, helping clinicians decide who needs specialist assessment first. #### Intended population Nurevo is designed for diverse, multilingual populations. Screening is not built around one language or culture. #### Inputs A short guided conversation on a phone or laptop is analysed across speech timing and voice, language, facial movement, and background information. #### Output The output is one explainable risk score. It shows which signals contributed most. #### Limitations Nurevo is at prototype stage and preparing clinical validation. No performance figures are published. It is not a diagnostic device, and it is not currently available for clinical use. #### Human oversight A clinician can see what informed the result. The score helps clinicians decide who needs specialist assessment first. #### Fairness Nurevo aims to report how the screening behaves across languages, ages and sexes, so differences can be seen and addressed. No performance figures are published at this prototype stage. ### Data protection Nurevo is designing the service around consent, UK GDPR and data minimisation. - **Consent.** People take part by choice, and know what the conversation is used for. - **UK GDPR.** The service is being designed to meet UK data protection law. - **Data minimisation.** The service is designed to collect and keep the least information needed for screening. ### Roadmap Where the work stands, without dates: 1. Working prototype (Completed) 2. Feasibility testing (Completed) 3. Model development (In progress) 4. Clinical studies (Planned) 5. The UK pathway for software as a medical device, overseen by the MHRA (Planned) ### How we plan to evaluate The evaluation plan is named here so it can be checked later. No results are published. - **Subgroup reporting.** Report how the screening behaves across languages, age groups and sexes, side by side. - **Comparison with specialist assessment.** Compare the risk score with the outcome of specialist assessment in registered clinical studies. - **Clinician review of explanations.** Ask clinicians whether the signals shown as contributing most help them decide who to see sooner. ### Regulatory status Where Nurevo stands today, in plain terms, and the route it intends to follow before any clinical use. - **What it is:** A screening and triage tool in development - **Clinical use:** Not currently available - **Conformity marking:** None held - **Regulatory clearance:** None held - **Intended route:** UK pathway for software as a medical device, overseen by the MHRA Nurevo holds no conformity marking and no regulatory clearance. Nurevo intends to follow the UK pathway for software as a medical device, overseen by the MHRA. The roadmap places this pathway after model development and clinical studies. The working prototype and feasibility testing are complete. No date is set. #### The intended route 1. **Build the evidence.** The working prototype and feasibility testing are complete. Model development is underway, followed by registered clinical studies. 2. **Quality and risk management.** Put a quality management system and clinical risk management in place. 3. **Conformity assessment.** Show that the software meets UK medical device requirements. 4. **Registration with the MHRA.** Register the device before any clinical use in the UK. No date is set for any step. This section will be updated as each step is reached. --- Nurevo Technology Limited is registered in Scotland, company number SC892389. Registered office: 89/63 Holyrood Road, Edinburgh, EH8 8BA. Nurevo is a screening and triage tool in development. It is not a diagnostic device and is not currently available for clinical use.